{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:38:41Z","timestamp":1782283121478,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T00:00:00Z","timestamp":1390953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Urinary tract infection (<jats:styled-content style=\"fixed-case\">UTI<\/jats:styled-content>) is a common clinical problem in diabetic patients; however, the relationship between <jats:styled-content style=\"fixed-case\">UTI<\/jats:styled-content> and glucosuria remains uncertain. To investigate the relationship, we examined the effect of glucosuria induced by sodium glucose cotransporter 2 (<jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content>) inhibitors on the progression of <jats:styled-content style=\"fixed-case\">UTI<\/jats:styled-content> in mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From 1\u2009day before transurethral inoculation with <jats:italic>Candida albicans<\/jats:italic>, female mice were treated orally once a day with an <jats:styled-content style=\"fixed-case\">SGLT2<\/jats:styled-content> inhibitor in different treatment regimens: (i) dapagliflozin at 10\u2009mg\/kg for 2, 3 or 7\u2009days, (ii) dapagliflozin at 0.1, 1 or 10\u2009mg\/kg for 3\u2009days and (iii) dapagliflozin, canagliflozin or tofogliflozin at 10\u2009mg\/kg for 3\u2009days. To evaluate the ascending <jats:styled-content style=\"fixed-case\">UTI<\/jats:styled-content>, the kidneys were removed 6\u2009days after the inoculation, and the number of viable <jats:italic>C. albicans<\/jats:italic> cells in kidney was measured as colony\u2010forming units (<jats:styled-content style=\"fixed-case\">CFU<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In mice treated with dapagliflozin, the number of <jats:italic>C. albicans<\/jats:italic> <jats:styled-content style=\"fixed-case\">CFU<\/jats:styled-content> in kidney increased in accordance with both treatment duration and dose. The number of <jats:styled-content style=\"fixed-case\">CFU<\/jats:styled-content> significantly increased when mice were treated with 10\u2009mg\/kg dapagliflozin or canagliflozin but not tofogliflozin. With dapagliflozin and canagliflozin, urine glucose concentration (<jats:styled-content style=\"fixed-case\">UGC<\/jats:styled-content>) significantly increased up to 24\u2009h after drug administration; with tofogliflozin, <jats:styled-content style=\"fixed-case\">UGC<\/jats:styled-content> significantly increased only up to 12\u2009h after drug administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data indicate that increased susceptibility to <jats:styled-content style=\"fixed-case\">UTI<\/jats:styled-content> is associated with a persistent increase in <jats:styled-content style=\"fixed-case\">UGC<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dom.12259","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T10:25:59Z","timestamp":1389176759000},"page":"622-627","source":"Crossref","is-referenced-by-count":21,"title":["Effect of <scp>SGLT2<\/scp> inhibitors in a murine model of urinary tract infection with <i>Candida albicans<\/i>"],"prefix":"10.1111","volume":"16","author":[{"given":"M.","family":"Suzuki","sequence":"first","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co. Ltd. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Chugai Research Institute for Medical Science, Inc. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co. Ltd. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Chugai Research Institute for Medical Science, Inc. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Honda","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co. Ltd. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co. Ltd. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kawabe","sequence":"additional","affiliation":[{"name":"Research Division Chugai Pharmaceutical Co. Ltd. Gotemba Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.2.510"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0570-3"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/431587"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200502000-00009"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01062-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.1.177"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-48-6-535"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.12.1737"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.07.042"},{"key":"e_1_2_7_11_1","first-page":"60","article-title":"Evaluation of the antibacterial effect of nalidixic acid in two experimental models of Escherichia coli pyelonephritis","volume":"49","author":"Prat V","year":"1968","journal-title":"Br J Exp Pathol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01111265"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2009.116"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00255-08"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF00265026","article-title":"Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice","volume":"28","author":"Gaulton GN","year":"1985","journal-title":"Diabetologia"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.697053"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.560181"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.689956"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-6-201203200-00003"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm701272q"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100332n"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300884k"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.13.6.939"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00409.2012"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00076-09"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.191593"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1472"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030555"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12259","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:16:59Z","timestamp":1760372219000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,29]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/dom.12259"],"URL":"https:\/\/doi.org\/10.1111\/dom.12259","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,29]]}}}